Well, let's start with top line, as you said, right, because then the bottom line falls through with us very, very easily, to answer your question. On – and as Tom indicated, as we look at the full year, we could draw various possibilities, various scenarios. We could. In our current guidance, I'm not suggesting for a second might even show up or close to show up. Problem is, frankly, as I indicated, we don't know. We don't know because we don't – we're trying to understand the impact of COVID-19 on our ecosystem and that this is still a very early stage in the whole process. But what we've seen so far is what happened in China, Asia, obviously. And that hit badly, big but – so it could come from two parts, demand and supply chain. What we saw in the supply chain was not much impact, partly because a lot of supply chain contract manufacturing and all that was not in China. Part of it was, but there was also inventory in the pipeline pre-COVID-19, so that kept supply chain going. So our supply chain has not been impacted to any meaningful level. On the demand side, there was slowdown. There has also been some level of recovery since then in China as this – as the pandemic in China starts to subside somewhat. Now having said that, we're looking over at the U.S., Europe now, and we're seeing that going into its full-blown glory. Can we extrapolate what we see in China over here? To be honest, we don't know. And so if you want to look at one right – one possible downside, and we plan – we have done plenty of it, you could say the revenues could drop, say, 10% – 5% to 10% from our $25 billion original forecast. And as Tom indicated, and I'll let Tom elaborate a bit more, what we're seeing is because of our high-margin products and revenues and to some extent, our variable OpEx, operating expense levels, we expect our EBITDA percentage, EBITDA percentage of revenue to still be comfortably over 50%. Tom?